Grace Therapeutics (GRCE) Asset Writedowns and Impairment (2020 - 2026)

Grace Therapeutics (GRCE) posted Asset Writedowns and Impairment of $407000.0 for Q3 2022, up 262.8% sequentially from -$250000.0 in Q2 2022.

Grace Therapeutics (GRCE) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends

Grace Therapeutics has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $407000.0 in Q3 2022.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $407000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $157000.0 (changed N/A YoY) and the FY2023 annual result came in at $28.7 million, changed N/A from the prior year.
Asset Writedowns and Impairment rose to $407000.0 in Q3 2022 per GRCE's latest filing, from -$250000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $3.7 million in Q3 2020 and troughed at -$3.7 million in Q1 2021.
A 3-year average of $39250.0 and a median of $78500.0 in 2022 frame the typical range for Asset Writedowns and Impairment.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Grace Therapeutics	37.99 Mn	37.99 Mn	-

Download Data